Evaluation of miR-146a Urinary Level as a Marker for Recurrence of Superficial Bladder Cancer after Transurethral Resection of Bladder Tumor (TUR-BT)

Background: The most prevalent malignancy affect the urinary system is bladder cancer which exhibits a markedly high recurrence rate. The level of urinary microRNA-146a (miR-146a) was significantly higher in superficial bladder cancer patients, and were decreased to normal range after transurethral resection of the bladder tumor (TUR-BT). Its level was increased again if there is recurrence of the superficial bladder tumor diagnosed by follow up cystoscopy. miR-146 may be a clinically important marker for diagnosis and recurrence of superficial bladder cancer and is used instead of follow up operations as follow up cystoscopy for follow up of recurrence . Objective: our work aims to detect a simple, reliable and noninvasive diagnostic and surveillance methods for follow up of superficial bladder cancer. Methodology: The level of miR-146a in urine of 30 superficial bladder cancer patients was evaluated by quantitative reverse transcription polymerase chain reaction assay using voided urine samples before, after TUR-BT and after 3, 6,9,12 months of resection and compared with the result of follow up cystoscopy. Results: miR-146a was significantly increased in urine samples from patients with superficial cancer bladder than in those from the normal individuals (P <.000). Elevated urinary miR-146a levels in patients with bladder cancer were lowered to the normal level after TUR-BT and increased again in those who have tumor recurrence and remain in a normal level in those who have no recurrence after follow up for 3 ,6, 9,12 months after surgery(P=. 007, P=.000 respectively).Conclusion: Our study concluded that urinary miR-146a may be useful as a novel noninvasive diagnostic and follow up marker, anticancer agent or therapeutic target for superficial cancer bladder, also for increasing our knowledge of cancer biology.

Download Full-text

The Significance of Simultaneous Transurethral Resection of Bladder Tumor and the Prostate in Patient who have Superficial Bladder Cancer with Bladder Outlet Obstruction

Korean Journal of Urology ◽

10.4111/kju.2008.49.9.791 ◽

2008 ◽

Vol 49 (9) ◽

pp. 791 ◽

Cited By ~ 1

Author(s):

Won Sik Ham ◽

Won Tae Kim ◽

Hyung Jin Jeon ◽

Dong Hoon Lee ◽

Young Deuk Choi

Keyword(s):

Bladder Cancer ◽

Transurethral Resection ◽

Bladder Outlet Obstruction ◽

Bladder Tumor ◽

Superficial Bladder Cancer ◽

Outlet Obstruction

Download Full-text

Two-step transurethral resection of bladder tumor can result in a better surgical quality and lower recurrence in patients with non-muscle invasive bladder cancer: a retrospective study

10.21203/rs.3.rs-16002/v1 ◽

2020 ◽

Author(s):

Wei-Lun Huang ◽

Chao-Yuan Huang ◽

Kuo-How Huang ◽

Yeong-Shiau Pu ◽

Hong-Chiang Chang ◽

...

Keyword(s):

Bladder Cancer ◽

Transurethral Resection ◽

Bladder Tumor ◽

Sampling Rate ◽

Invasive Bladder Cancer ◽

Detrusor Muscle ◽

Muscle Invasive Bladder Cancer ◽

Free Survival ◽

Muscle Invasive

Abstract Background Current protocols for transurethral resection of bladder tumor (TURBT) are still unstandardized, and outcomes are also uneven in different protocols. In our medical center, we performed two-step TURBT that the resection of bladder tumor is made in two steps- exophytic parts first and tumor bases second. The purpose is to improve tumor eradication and increase detrusor muscle sampling rates. The aim of current study is to evaluate clinical outcomes and detrusor muscle sampling rate of two-step TURBT in patients with non-muscle invasive bladder cancer (NMIBC). Methods We conducted a retrospective review from a prospective database. From January 2012 to December 2017, patients who had newly diagnosed NMIBC with a follow-up period of more than 2 years were enrolled. Patients with concomitant or subsequent upper urinary tract urothelial carcinoma (UTUC) were excluded. Patients were categorized into the two-step TURBT (TR) and the conventional TURBT (CR) groups. The primary endpoints were recurrence and progression rates. The secondary endpoints were recurrence-free survival (RFS), progression-free survival (PFS), and the detrusor muscle sampling rate. Results There were 205 patients included in our study, with 151 patients in the TR group and 54 patients in the CR group. The median follow-up period was 40.5 months. There were lower recurrence rate ( P = 0.015), higher detrusor muscle sampling rate ( P = 0.043), and better RFS (Log-Rank P= 0.007) in the TR group. Two-step TURBT was also associated with better RFS in both univariate ( P =0.009) and multivariate ( P =0.003) Cox proportional hazards regression. Conclusions In patients with NMIBC, Two-step TURBT results in higher detrusor muscle sampling rate and better disease outcomes. The findings suggest that Two-step TURBT is a better surgical method for treating NMIBC.

Download Full-text

Limited significance of routine excretory urography in the follow-up of patients with superficial bladder cancer after transurethral resection

BJU International ◽

10.1111/j.1464-410x.2006.06032.x ◽

2006 ◽

Vol 97 (4) ◽

pp. 720-723 ◽

Cited By ~ 8

Author(s):

HIDEAKI MIYAKE ◽

ISAO HARA ◽

KAZUKI YAMANAKA ◽

TAKA-AKI INOUE ◽

MASATO FUJISAWA

Keyword(s):

Bladder Cancer ◽

Transurethral Resection ◽

Superficial Bladder Cancer ◽

Excretory Urography

Download Full-text

The effect of holmium laser resection versus standard transurethral resection on non-muscle-invasive bladder cancer: A systematic review and meta-analysis

10.21203/rs.2.12172/v1 ◽

2019 ◽

Cited By ~ 1

Author(s):

Changlong Li ◽

Liang Gao ◽

Jindong Zhang ◽

Xiaokang Yang ◽

Chuan Liu

Keyword(s):

Bladder Cancer ◽

Urethral Stricture ◽

Transurethral Resection ◽

Bladder Tumor ◽

Obturator Nerve ◽

Muscle Invasive Bladder Cancer ◽

Laser Resection ◽

Muscle Invasive ◽

Time Of Operation

Abstract Purpose: To explore the advantages and limitations of holmium laser resection of the bladder tumor (HOLRBT) versus standard transurethral resection of the bladder tumor (TURBT) in the treatment of non-muscle-invasive bladder cancer (NMIBC). Methods: The eligible studies were selected from the following databases: PubMed, Cochrane Library and Embase. Studies comparing HOLRBT and TURBT for patients with NMIBC were included. The outcomes of interest were time of operation, catheterization, and hospitalization, rates of recurrence and perioperative complications, including obturator nerve reflex, bladder perforation, bladder irritation and urethral stricture. Results of all data were compared and analyzed by Review Manager 5.3. Results: A total of 9 comparative studies were finally included for analysis. Pooled data demonstrated that HOLRBT could significantly reduce the time in catheterization and hospitalization, the rates of recurrence in 2 years of follow-up, obturator nerve reflex, bladder perforation, bladder irritation compared with those in TURBT, respectively. However, no significant difference could be found between HOLRBT and TURBT in the time of operation, rate of recurrence at 1-year follow-up and urethral stricture. Conclusions: The results of our research showed that HOLRBT would be a better choice than TURBT for patients with NMIBC.

Download Full-text

Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Non-muscle Invasive Bladder Cancer Patients: Initial Intravesical Bacillus Calmette-Guerin Treatment After Transurethral Resection of Bladder Tumor Setting

Frontiers in Oncology ◽

10.3389/fonc.2018.00642 ◽

2019 ◽

Vol 8 ◽

Cited By ~ 6

Author(s):

Hyeong Dong Yuk ◽

Chang Wook Jeong ◽

Cheol Kwak ◽

Hyeon Hoe Kim ◽

Ja Hyeon Ku

Keyword(s):

Bladder Cancer ◽

Cancer Patients ◽

Transurethral Resection ◽

Poor Prognosis ◽

Bladder Tumor ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Muscle Invasive Bladder Cancer ◽

Lymphocyte Ratio ◽

Muscle Invasive

Download Full-text

En Bloc Resection of Bladder Tumor—Is It the Way Forward?

Frontiers in Surgery ◽

10.3389/fsurg.2021.685506 ◽

2021 ◽

Vol 8 ◽

Author(s):

Christian Daniel Fankhauser ◽

Marian Severin Wettstein ◽

Luca Afferi ◽

Nico Christian Grossmann ◽

Hugh Mostafid

Keyword(s):

Bladder Cancer ◽

Cancer Patients ◽

Transurethral Resection ◽

Bladder Tumor ◽

En Bloc Resection ◽

Bloc Resection ◽

80 And Over ◽

Bladder Tumors ◽

En Bloc ◽

Translational Studies

Transurethral resection of bladder tumors (TURBT) represents the cornerstone in diagnosis and treatment of bladder cancer but recurrence is observed in up to 80% and over- or understaging with TURBT is common. A more recent development to overcome these limitations represents en-bloc resection of bladder tumors (ERBT) which offers several advantages over TURBT. In this report, we briefly review studies assessing outcomes of bladder cancer patients undergoing ERBT. Most randomized and non-randomized trial demonstrate improvement in clinical outcomes for ERBT over TURBT, however more pathological and translational studies are warranted.

Download Full-text

Interleuchina 2 nel trattamento dei tumori superficiali della vescica

Urologia Journal ◽

10.1177/039156039406101s10 ◽

1994 ◽

Vol 61 (1_suppl) ◽

pp. 41-42

Author(s):

E. Gastaldi ◽

S. Benvenuti ◽

B. Mennini ◽

M. Iacoviello ◽

M. Caviglione ◽

...

Keyword(s):

Bladder Cancer ◽

Transurethral Resection ◽

Superficial Bladder Cancer ◽

Interleukin 2 ◽

Subcutaneous Immunotherapy ◽

Bladder Tumours

The Authors report their experience with interleukin 2 given intralesionally and subcutaneously in superficial bladder tumours after transurethral resection. The present study was carried out to evaluate the efficacy and tollerability of a subcutaneous immunotherapy with IL-2 in these tumours. The study included 16 patients with superficial bladder cancer (Ta-T1 G1-G2) and it showed that IL-2 is an effective and well-tolerated treatment of superficial bladder cancer but a longer follow-up period is necessary.

Download Full-text

Long-term Effect of Transurethral Resection of Bladder Tumor Combined with Intravesical Instillation of Pirarubicin on Immune Function in Superficial Bladder Cancer

10.36468/pharmaceutical-sciences.spl.9 ◽

2020 ◽

Vol 20 (s2) ◽

Author(s):

R. Feng

Keyword(s):

Bladder Cancer ◽

Immune Function ◽

Transurethral Resection ◽

Bladder Tumor ◽

Superficial Bladder Cancer ◽

Intravesical Instillation ◽

Term Effect ◽

Long Term Effect

Download Full-text

Clinicopathological features and oncological outcomes of urothelial carcinoma involving the ureterovesical junction

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyab143 ◽

2021 ◽

Author(s):

Takahiro Oshina ◽

Satoru Taguchi ◽

Jimpei Miyakawa ◽

Yoshiyuki Akiyama ◽

Yusuke Sato ◽

...

Keyword(s):

Bladder Cancer ◽

Urothelial Carcinoma ◽

Transurethral Resection ◽

Bladder Tumor ◽

Treatment Strategies ◽

Upper Tract Urothelial Carcinoma ◽

Radical Nephroureterectomy ◽

Ureterovesical Junction ◽

Upper Tract

Abstract Background The ureterovesical junction is the boundary between the urinary bladder and upper urinary tract. Because treatment strategies for bladder cancer and upper tract urothelial carcinoma are entirely different, urothelial carcinoma involving the ureterovesical junction requires special attention. Nevertheless, studies focusing on the disease are lacking. Methods We reviewed consecutive patients with urothelial carcinoma treated via either transurethral resection of bladder tumor (n = 2791) or radical nephroureterectomy (n = 292) between 2000 and 2020 and identified those with bladder cancer involving the ureteral orifice (n = 64) and those with upper tract urothelial carcinoma involving the intramural ureter (≤2 cm) (n = 41). After excluding overlapping cases (n = 24), 80 patients with urothelial carcinoma involving the ureterovesical junction were analyzed. Results The initial symptoms or reasons for diagnosing urothelial carcinoma involving the ureterovesical junction were hematuria (n = 30), hydronephrosis (n = 21), follow-up examinations for prior urothelial carcinoma (n = 13), screening examinations (n = 7), frequent urination (n = 6) and unknown causes (n = 3). During a median follow-up period of 42 months, 18 patients died of urothelial carcinoma. The definitive surgical treatments for urothelial carcinoma involving the ureterovesical junction were transurethral resection of bladder tumor alone (n = 26), radical nephroureterectomy (n = 41) and radical cystectomy (n = 13), with different treatments having different cancer-specific survivals. Multivariate analyses identified T stage (≥T2) as an independent predictor of shorter cancer-specific survival. Conclusions Given the positional property of urothelial carcinoma involving the ureterovesical junction, the profiles of patients with the disease were highly heterogeneous. Further optimization of treatment strategies for urothelial carcinoma involving the ureterovesical junction is urgently warranted for better clinical outcomes.

Download Full-text